基于 CXCR4 的成像剂。
CXCR4-based imaging agents.
机构信息
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland 21231, USA.
出版信息
J Nucl Med. 2011 Nov;52(11):1665-9. doi: 10.2967/jnumed.111.097733.
Abstract
Chemokine receptor 4 (CXCR4)-chemokine ligand 12 (CXCL12) interactions have been shown to play key roles in cancer cell survival, proliferation, chemotaxis, homing, adhesion, tumor angiogenesis, and resistance to conventional and targeted therapies. Given its extensive involvement in cancer progression, the CXCR4-CXCL12 axis has been considered a therapeutic target. Several inhibitors blocking this signaling cascade are in phase I trials. Because CXCR4 is constitutively expressed in a wide variety of normal tissues, patient stratification and noninvasive monitoring would improve therapeutic outcome and reduce unnecessary toxicities. This review focuses on recent developments in CXCR4-based imaging agents and their potential role in the molecular diagnosis and treatment of cancer.
摘要
趋化因子受体 4（CXCR4）-趋化因子配体 12（CXCL12）相互作用已被证明在癌细胞存活、增殖、趋化性、归巢、黏附、肿瘤血管生成以及对常规和靶向治疗的耐药性中发挥关键作用。鉴于其在癌症进展中的广泛参与，CXCR4-CXCL12 轴已被视为治疗靶点。几种阻断这种信号级联的抑制剂正在进行 I 期临床试验。由于 CXCR4 在多种正常组织中持续表达，因此患者分层和非侵入性监测将改善治疗效果并减少不必要的毒性。本文重点介绍了基于 CXCR4 的成像剂的最新进展及其在癌症分子诊断和治疗中的潜在作用。
相似文献
1
CXCR4-based imaging agents.基于 CXCR4 的成像剂。
J Nucl Med. 2011 Nov;52(11):1665-9. doi: 10.2967/jnumed.111.097733.
2
The intricate role of CXCR4 in cancer.CXCR4在癌症中的复杂作用。
Adv Cancer Res. 2014;124:31-82. doi: 10.1016/B978-0-12-411638-2.00002-1.
3
Imaging agents for the chemokine receptor 4 (CXCR4).趋化因子受体 4（CXCR4）的成像剂。
Chem Soc Rev. 2012 Aug 7;41(15):5239-61. doi: 10.1039/c2cs35085h. Epub 2012 Jun 28.
4
Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.成像 CXCL12-CXCR4 信号在卵巢癌治疗中的作用。
PLoS One. 2013;8(1):e51500. doi: 10.1371/journal.pone.0051500. Epub 2013 Jan 23.
5
CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy.CXCL12/CXCR4 信号转导在疾病中的作用及其在靶向治疗中的分子方法。
Immunol Lett. 2020 Jan;217:91-115. doi: 10.1016/j.imlet.2019.11.007. Epub 2019 Nov 17.
6
The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.CXCL12（SDF-1）/CXCR4 趋化因子轴：致癌特性、分子靶向和用于癌症治疗的合成及天然产物 CXCR4 抑制剂。
Chin J Nat Med. 2018 Nov;16(11):801-810. doi: 10.1016/S1875-5364(18)30122-5.
7
Chemokine receptor - Directed imaging and therapy.趋化因子受体靶向成像与治疗。
Methods. 2017 Nov 1;130:63-71. doi: 10.1016/j.ymeth.2017.09.002. Epub 2017 Sep 12.
8
A review on CXCR4/CXCL12 axis in oncology: no place to hide.CXCR4/CXCL12 轴在肿瘤学中的研究进展：无处可藏。
Eur J Cancer. 2013 Jan;49(1):219-30. doi: 10.1016/j.ejca.2012.05.005. Epub 2012 Jun 9.
9
CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.CXCR4/CXCL12轴通过Akt信号通路促进VEGF介导的肿瘤血管生成。
Biochem Biophys Res Commun. 2007 Aug 3;359(3):716-22. doi: 10.1016/j.bbrc.2007.05.182. Epub 2007 Jun 4.
10
Molecular imaging of chemokine receptor CXCR4.趋化因子受体 CXCR4 的分子成像。
Theranostics. 2013;3(1):76-84. doi: 10.7150/thno.4835. Epub 2013 Jan 15.
引用本文的文献
1
PET imaging of CXCR4 expression using [F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors.使用 [F]AlF-NOTA-QHY-04 进行 CXCR4 表达的 PET 成像，用于血液恶性肿瘤和实体肿瘤。
Theranostics. 2024 Sep 30;14(16):6337-6349. doi: 10.7150/thno.99025. eCollection 2024.
2
Chemokine Receptor 4-Targeted PET/CT with [Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [Ga]pentixafor PET/CT.用[镓]喷替肽进行趋化因子受体4靶向PET/CT在新诊断多发性骨髓瘤中的应用：与[镓]喷替沙氟PET/CT的比较研究
Mol Imaging Biol. 2024 Dec;26(6):986-994. doi: 10.1007/s11307-024-01953-7. Epub 2024 Sep 20.
3
Construction of CXCR4 Receptor-Targeted CuFeSe Nano Theranostic Platform and Its Application in MR/CT Dual Model Imaging and Photothermal Therapy.构建 CXCR4 受体靶向的 CuFeSe 纳米诊疗平台及其在磁共振/计算机断层扫描双模态成像和光热治疗中的应用。
Int J Nanomedicine. 2024 Sep 7;19:9213-9226. doi: 10.2147/IJN.S470367. eCollection 2024.
4
Chemokine receptor PET imaging: Bridging molecular insights with clinical applications.趋化因子受体 PET 成像：将分子见解与临床应用联系起来。
Nucl Med Biol. 2024 Jul-Aug;134-135:108912. doi: 10.1016/j.nucmedbio.2024.108912. Epub 2024 Apr 18.
5
LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration.LPA1 介导的 CXCR4 抑制作用可减弱 CXCL12 诱导的信号转导和细胞迁移。
Cell Commun Signal. 2023 Sep 25;21(1):257. doi: 10.1186/s12964-023-01261-7.
6
Small-Molecule Fluorescent Ligands for the CXCR4 Chemokine Receptor.小分子荧光配体用于趋化因子受体 CXCR4。
J Med Chem. 2023 Apr 13;66(7):5208-5222. doi: 10.1021/acs.jmedchem.3c00151. Epub 2023 Mar 21.
7
The Role of [Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review.[镓]镓-喷替沙氟PET/CT或PET/MRI在淋巴瘤中的作用：一项系统评价
Cancers (Basel). 2022 Aug 5;14(15):3814. doi: 10.3390/cancers14153814.
8
CXCR4-targeted theranostics in oncology.肿瘤学中 CXCR4 靶向治疗学。
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4133-4144. doi: 10.1007/s00259-022-05849-y. Epub 2022 Jun 8.
9
CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells.CP-25 通过促进 GRK2 诱导的内皮细胞中 CXCR4-ERK1/2 信号通路下调发挥抗血管生成作用，从而抑制佐剂诱导的关节炎大鼠模型的血管生成。
Mol Med Rep. 2019 Dec;20(6):4831-4842. doi: 10.3892/mmr.2019.10765. Epub 2019 Oct 23.
10
Repopulating hematopoietic stem cells from steady-state blood before and after culture are enriched in the CD34CD133CXCR4 fraction.培养前后的稳态血液中的造血干细胞再群体化在 CD34CD133CXCR4 部分得到富集。
Haematologica. 2018 Oct;103(10):1604-1615. doi: 10.3324/haematol.2017.183962. Epub 2018 Jun 1.
本文引用的文献
1
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells.一种合成生物学方法揭示了 CXCR4-G13-Rho 信号轴驱动转移性乳腺癌细胞穿越血管内皮的迁移。
Sci Signal. 2011 Sep 20;4(191):ra60. doi: 10.1126/scisignal.2002221.
2
PET imaging of CXCR4 receptors in cancer by a new optimized ligand.利用新型优化配体对癌症中CXCR4受体进行正电子发射断层扫描成像
ChemMedChem. 2011 Oct 4;6(10):1789-91. doi: 10.1002/cmdc.201100320. Epub 2011 Jul 20.
3
Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7.通过趋化因子受体 CXCR4 和 CXCR7 进行肿瘤近红外分子成像。
Clin Exp Metastasis. 2011 Dec;28(8):713-20. doi: 10.1007/s10585-011-9403-y. Epub 2011 Jul 7.
4
CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.CXCR7/CXCR4 异二聚体持续募集β-arrestin 以增强细胞迁移。
J Biol Chem. 2011 Sep 16;286(37):32188-97. doi: 10.1074/jbc.M111.277038. Epub 2011 Jul 5.
5
Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.在人源肿瘤异种移植模型中评估 CXCR4 表达的影像学研究：单环酰胺 64Cu-AMD3465 的评价。
J Nucl Med. 2011 Jun;52(6):986-93. doi: 10.2967/jnumed.110.085613.
6
PET imaging of CXCR4 using copper-64 labeled peptide antagonist.使用放射性核素标记的 CXCR4 肽拮抗剂进行 PET 成像。
Theranostics. 2011;1:251-62. doi: 10.7150/thno/v01p0251. Epub 2011 Apr 19.
7
Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide.双模态 CXCR4 拮抗肽的合成与评价。
Bioconjug Chem. 2011 May 18;22(5):859-64. doi: 10.1021/bc2000947. Epub 2011 Apr 19.
8
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.人前列腺癌转移定位于造血干细胞龛，在小鼠骨髓中建立立足点。
J Clin Invest. 2011 Apr;121(4):1298-312. doi: 10.1172/JCI43414. Epub 2011 Mar 23.
9
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?CXCL12(SDF1alpha)-CXCR4/CXCR7 通路抑制：一种新兴的抗肿瘤治疗增敏剂？
Clin Cancer Res. 2011 Apr 15;17(8):2074-80. doi: 10.1158/1078-0432.CCR-10-2636. Epub 2011 Feb 24.
10
Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.使用 64Cu-AMD3100 对表达人趋化因子受体 CXCR4 的肿瘤进行正电子发射断层成像。
Mol Imaging Biol. 2012 Feb;14(1):106-14. doi: 10.1007/s11307-010-0466-y.
Zotero 插件